期刊文献+

基于EDC/sulfo-NHS的羧基化SPIO表面抗体耦联 被引量:2

Conjugation of antibody on carboxyl-SPIO nanoparticles based on EDC/sulfo-NHS
下载PDF
导出
摘要 目的:研究羧基化超顺磁性氧化铁纳米颗粒(SPIO)纳米粒子与anti-EMMPRIN单克隆抗体耦联的有效方法,考察不同pH条件下进行耦联反应的效率及anti-EMMPRIN-SPIO的粒径水平。方法:用EDC/sulfo-NHS法将anti-EMMPRIN单克隆抗体耦联到羧基化SPIO纳米粒子表面,用动态光散射法检测所得anti-EMMPRIN-SPIO的粒径,并用Bradford法和SDS-PAGE法分析不同酰胺化pH条件下的耦联效率。结果:通过EDC/sulfo-NHS的作用,anti-EMMPRIN单克隆抗体有效地耦联到羧基化SPIO表面。pH7.8时酰胺化的anti-EMMPRIN-SPIO纳米粒子的粒径最小,为63.15 nm。pH6.8和pH7.3条件下酰胺化所得上清中的抗体含量较低,分别为1.943 2×10-4g/L和3.511 1×10-4g/L,SDS-PAGE凝胶图谱上可明显观察到pH6.8、pH7.3和pH7.8条件下所制备样品的谱带分别位于55 000和25 000。结论:EDC/sulfo-NHS法是anti-EMMPRIN单克隆抗体耦联于羧基化SPIO表面的有效方法。在pH6.8、pH7.3、pH7.8条件下酰胺化耦联效率较高,所制备的anti-EMMPRIN-SPIO粒径较小。pH值对EDC/sulfo-NHS介导的耦联反应的耦联效率及anti-EMMPRIN-SPIO的粒径有较大影响。 Objective:To conjugate anti-EMMPRIN monoclonal antibody on the surface of carboxyl-SPIO nanoparticles. The efficiency of superparamagnetic iron oxide (SPIO) conjugated with anti-EMMPRIN monoclonal antibody and the size of anti- EMMPRIN-SPIO were investigated in different pH values. Methods:Anti-EMMPRIN monoclonal antibody conjugated SPIO nanoparticles were performed through a coupling strategy of EDC and sulfo-NHS. Bradford assay and SDS-PAGE analysis were used for measuring the conjugation efficiency. The size of anti-EMMPRIN-SPIO was evaluated by dynamic light scattering method. Results: The smallest diameter of 63.15 nm was obtained when pH 7.8 was used. The lower concentration of antibody in supernatant with pH6.8 and pH7.3 was 1.943 2×10^-4 g/L and 3.511 1 ×10^-4g/L, respectively. Anti-EMMPRIN mAb was detected in lanes of pH6.8, pH7.3 and pH7.8 which revealed two bands with weight of 55 000 and 25 000. Conclusion:EDC/sulfo-NHS method is an efficient method for conjugating anti-EMMPRIN monoclonal antibody on SPIO nanoparticles. Under the amidation condition with pH value of 6.8, 7.3 and 7.8, higher conjugation efficiency and smaller size of anti-EMMPRIN-SPIO were obtained. The results showed that pH value is a very important factor which influences conjugation efficiency and the size of anti-EMMPRIN-SPIO.
出处 《南京医科大学学报(自然科学版)》 CAS CSCD 北大核心 2013年第4期480-484,共5页 Journal of Nanjing Medical University(Natural Sciences)
基金 江苏省生物材料与器件重点实验室开放基金(2012LBMD05) 环境医学工程教育部重点实验室开放基金(2012EME005)
关键词 EDC sulfo-NHS 超顺磁性氧化铁纳米颗粒 EMMPRIN单克隆抗体 耦联 EDC/sulfo-NHS SPIO anti-EMMPRIN monoclonal antibody conjugation
  • 相关文献

参考文献16

  • 1Bao J,Chen W,Liu T,et al. Bifunctional Au-Fe304 nanoparticles for protein separation[J]. ACS Nano, 2007,1 (4) : 293-298.
  • 2Schladt TD,Schneider K,Schild H,et al. Synthesis and bio-functionalization of magnetic nanoparticles for medical diagnosis and treatment[ J ]. Dalton Trans, 2011,40: 6315- 6343.
  • 3Shi J,Votruba AR,Farokhzad OC ,et al. Nanotechnology in drug delivery and tissue engineering:from discovery to applications [ J ]. Nano Lett, 2010,10 (9) : 3223-3230.
  • 4Baby Tr,Ramaprabhu S. SiO2 coated Fe304 magnetic nanoparticle dispersed muhiwalled carbon nanotubes based amperometrie glucose biosensor[J ]. Talanta, 2010, 80 (5) : 2016-2022.
  • 5Maeng JH, Lee DH, Jung KH, et al. Multifunetional dox- orubiein loaded superparamagnetic iron oxide nanoparti- cles for chemotherapy and magnetic resonance imaging in liver cancer[J ]. Biomaterials, 2010,31 (18) :4995-5006.
  • 6Biswas C,Zhang Y,DeCastro R,et al. The human tumor cell-derived eollagenase stimulatory factor (renamed EMNPRIN) is a member of the immunoglobulin super- family[J]. Cancer Res, 1995,55(2) :434-439.
  • 7Riethdorf S, Reimers N, Assmann V, et al. High incidence of EMMPRIN expression in human tumors[J]. Int J Can- cer, 2006,119(8) : 1800-1810.
  • 8Yu S, Chow GM. Carboxyl group (-CO2H) functionalized ferrimagnetic iron oxide nanoparticles for potential bio- applications [J]. J Mater Chem, 2004,14: 2781-2786.
  • 9Ge1inas S,Finch JA,Vreugdenhil AJ. Coupling of di- ethylenetriamine to carboxyl-terminated magnetic parti- cle[J]. Colloids Sur A:Physicochemi Eng Asp,2000,164 (2) :257-266.
  • 10Zou P,Yu Y,Wang YA,et al. Superparamagnetic iron ox- ide nanotheranostics for targeted cancer cell imaging and pH-dependent intracellular drug release[J]. Mol Pharm, 2010,7(6) : 1974-1984.

同被引文献18

  • 1Kenji K, Hironori U, Hideya Y, et al. Tenascin-C is associated with coronary plaque instability in patients with acute coronary syndromes [ J ]. Circ J, 2004,68 (3) : 198-203.
  • 2Wallner K, Li C, Shah PK, et al. Tenascin-C is expressed in macrophage-rich human coronary atherosclerotic plaque [ J ]. Circulation, 1999,99(10) : 1284-1289.
  • 3Wang L, Wang W, Shah PK, et al. Deletion of tenascin-C gene exacerbates atherosclerosis and induces intraplaque hemorrhage in Apo-E-deficient mice[Jl. Cardiovasc Pathol, 2012,21 (5) :398- 413. DOI: 10. 1016/j. carpath. 2011.12. 005.
  • 4Chen Y, Kennedy D J, Ramakrishnan DP, et al. Oxidized LDL- bound CD36 recruits an Na+/K+-ATPase-Lyn complex in macrophages that promotes atherosclerosis [ J ]. Sci Signal, 2015,8 (393) :ragl. DOI: 10. l126/scisignal, aaa9623.
  • 5Imanaka-Yoshida K, Aoki H. Tenascin-C and in the development and diseases of cardiovascular system [ J ]. Front Physiol, 2014,5:283. DOI: 10. 3389/fphys. 2014. 00283.
  • 6Liu R, He Y, Li B, et al. Tenascin-C produced by oxidized LDL- stimulated macrophages increases foam cell formation through Toll- like receptor-4[J]. Mol Cells, 2012,34(1 ) :35-41. DOI: 10. 1007/s10059-O12-0054-x.
  • 7Golledge J, Clancy P, Maguire J, et al. The role of tenascin C in cardiovascular disease [ J ]. Cardiovase Res, 2011,92 ( 1 ) : 19-28. DOI: 10. 1093/evr/cvr183.
  • 8Minear MA, Crosslin DR, Sutton BS, et al. Polymorphic variants in tenascin-C (TNC) are associated with atherosclerosis and coronary artery disease [ J ]. Hum Genet, 2011,129 (6) :641-654. DOI: 10. 1007/s00439-011-0959-z.
  • 9Silvello D, Narvaes LB, Albuquerque LC, et al. Serum levels and polymorphisms of matrix metalloproteinases (MMPs) in carotidartery atherosclerosis: higher MMP-9 levels are associated with plaque vulnerability[ J]. Biomarkers, 2014,19( 1 ) :49-55. DOI: 10.3109/1354750X. 2013. 866165.
  • 10Sakamoto N, Hoshino Y, Misaka T, et al. Serum tenascin-C level is associated with coronary plaque rupture in patients with acute coronary syndrome [ J 1- Heart Vessels, 2014,29 (2) : 165-170. DOI: 10. 1007/s00380-013-0341-2.

引证文献2

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部